Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Primary Objective:

• Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed to be tested in the expansion part of the study in the NSQ NSCLC population
• Expansion part (including participants treated at the recommended dose for expansion [RDE] from the Safety Run-in part): to assess the antitumor activity of several dose levels (DLs; if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population

Secondary Objectives:

• To assess the safety and tolerability of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, and platinum-based chemotherapy with pemetrexed in the NSQ NSCLC population
• To assess the antitumor activity of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
• To assess the durability of the response to treatment with several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
• To assess the antitumor activity of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy in the NSQ NSCLC population
• To assess the pharmacokinetics (PK) of tusamitamab ravtansine, pembrolizumab, pemetrexed, cisplatin, and carboplatin, each when given in combination as a doublet (tusamitamab ravtansine + pembrolizumab) or a triplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy) or a quadruplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy + pemetrexed)
• To assess the immunogenicity of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum based chemotherapy with or without pemetrexed

Study Overview

• Status: Terminated
• Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
• Intervention / Treatment: Drug: SAR408701 (Tusamitamab ravtansine); Drug: Pembrolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed

Detailed Description

The expected duration of study intervention for participants may vary, based on disease progression date; median expected duration of study per participant is estimated at 10 months (up to 1 month for screening, a median of 6 months for treatment, a median of 1 month for EOT, and follow-up visit 90 days after the last IMP administration).

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Phase 2

Contacts and Locations

Study Locations

• Brazil
  • Rio Grande do Norte
    • Natal, Rio Grande do Norte, Brazil, 59062-000
      • Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004
• Chile
  • Santiago, Chile, 7500713
    • Orlandi Oncologia General Salvo 159, Providencia_Investigational Site Number :1520002
  • Santiago, Chile, 8241470
    • ICEGCLINIC Avenida Serafín Zamora 190 Torre B, piso 4. La Florida_Investigational Site Number :1520006
  • La Araucanía
    • Temuco, La Araucanía, Chile, 4780000
      • Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005
  • Región de Valparaíso
    • Viña del Mar, Región de Valparaíso, Chile, 2520598
      • ONCOCENTRO APYS Av. La Marina 1702, 2do piso, Viña del Mar_Investigational Site Number :1520003
• Czechia
  • Olomouc, Czechia, 77900
    • Fakultní nemocnice Olomouc Onkologická klinika I.P. Pavlova 6_Site Number :2030001
  • Ostrava - Vitkovice, Czechia, 70384
    • Nemocnice AGEL Ostrava - Vitkovice Plicní oddělení Zalužanského 2214/35_Site Number :2030002
• France
  • Avignon, France, 84918
    • Institut Sainte-Catherine 250 Chemin de Baigne-Pieds_Investigational Site Number :2500005
  • Brest, France, 29200
    • CHRU BREST 5 Avenue Foch_Investigational Site Number :2500003
  • Pessac, France, 33600
    • Centre François Magendie Hôpital du Haut Lévèque Av.de Magellan_Investigational Site Number :2500001
  • Poitiers, France, 86021
    • Pôle régional de Cancérologie 2 rue de la Milèterie BP 577_Investigational Site Number :2500004
• Hungary
  • Budapest, Hungary, 1122
    • Országos Onkológiai Intézet Ráth György u. 7_Investigational Site Number :3480002
  • Farkasgyepü, Hungary, 8582
    • Veszprém Megyei Tüdőgyógyintézet 049/2 Hrsz_Investigational Site Number :3480004
• Israel
  • Ramat Gan, Israel, 5266202
    • Investigational Site Number : 3760001
  • Tel Aviv, Israel, 64239
    • Investigational Site Number : 3760002
• Spain
  • Las Palmas, Spain, 35016
    • Investigational Site Number : 7240002
  • Madrid, Spain, 28041
    • Investigational Site Number : 7240001
  • Madrid, Spain, 28040
    • Investigational Site Number : 7240004
  • A Coruña [La Coruña]
    • A Coruña, A Coruña [La Coruña], Spain, 15006
      • Investigational Site Number : 7240005
  • Catalunya [Cataluña]
    • Badalona, Catalunya [Cataluña], Spain, 08916
      • Investigational Site Number : 7240006
  • Principality of Asturias
    • Oviedo, Principality of Asturias, Spain, 33011
      • Investigational Site Number : 7240007
• United States
  • Kansas
    • Westwood, Kansas, United States, 66205
      • KU Medical Center_Investigational Site Number :8400002

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria :

• Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations.
• No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease).
• Expression of CEACAM5 as demonstrated prospectively by a centrally assessed Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 1% of the tumor cell population in archival tumor sample (or if not available fresh biopsy sample).
• Measurable disease based on RECIST 1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
• Life expectancy of at least 3 months

Exclusion criteria:

• Medical condition requiring concomitant administration of a medication with a strong CYP3A inhibitor.
• Uncontrolled brain metastases and history of leptomeningeal disease.
• Significant concomitant illness, including any severe medical condition that, in the opinion of the investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
• History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
• History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C infection.
• History of active autoimmune disease that has required systemic treatment in the past 2 years.
• History of allogeneic tissue/solid organ transplantation.
• Active infection requiring IV systemic therapy within 2 weeks prior to randomization or active tuberculosis.
• Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
• Non-resolution of any prior treatment-related toxicity to < Grade 2 according to NCI CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy.
• Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact lenses is not permitted.
• Symptomatic herpes zoster within 3 months prior to screening.
• Significant allergies to humanized monoclonal antibodies.
• Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
• Concurrent treatment with any other anticancer therapy.
• Have received prior chemotherapy treatment for advanced/metastatic NSCLC.
• The patient is a candidate for a curative treatment with either surgical resection and/or chemoradiation
• Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for any investigational treatment).
• Any prior therapy targeting CEACAM5.
• Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.
• Any prior maytansinoid treatment (DM1 or DM4 ADC).
• Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication. Daily steroid replacement therapy or any corticosteroid premedication if applicable are allowed.
• Any radiation therapy to lung >30 Gy within 6 months of first study intervention administration.
• Has received or will receive a live vaccine within 30 days prior to the first study intervention administration.
• Any major surgery within the preceding 3 weeks of the first study intervention administration.

Prior/concurrent clinical study experience

• Current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
• Poor organ function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tusamitamab ravtasine 150 mg/m^2 + Pembrolizumab; Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda
Experimental: Tusamitamab ravtasine 170 mg/m^2 + Pembrolizumab; Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda
Experimental: Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin; Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda; Drug: Carboplatin; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Drug: Cisplatin; Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
Experimental: Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin; Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda; Drug: Carboplatin; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Drug: Cisplatin; Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
Experimental: Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed; Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda; Drug: Carboplatin; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Drug: Cisplatin; Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous; Drug: Pemetrexed; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Experimental: Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed; Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.	Drug: SAR408701 (Tusamitamab ravtansine); Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Tusamitamab ravtansine; Drug: Pembrolizumab; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Other Names: Keytruda; Drug: Carboplatin; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous; Drug: Cisplatin; Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous; Drug: Pemetrexed; Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs)	DLTs were defined as: a) Hematological abnormalities: grade 4 neutropenia for 7 or more consecutive days, grade 3 to 4 neutropenia complicated by fever (temperature ≥38.5 degree Celsius on more than 1 occasion) or microbiologically or radiographically documented infection, grade ≥3 thrombocytopenia associated with clinically significant bleeding requiring clinical intervention; b) Non-hematological abnormalities: grade 4 non-hematologic adverse event (AE), except AE symptoms related to the underlying disease as per the Investigator's judgment, grade ≥3 keratopathy. In addition, any other AE that the recruiting Investigators and sponsor deemed to be dose-limiting, regardless of its grade, was also considered as DLT.	Cycle 1 Day 1 up to Cycle 1 Day 21 (cycle duration=3 weeks)
Doublet Cohort: Objective Response Rate (ORR)	ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 158.4 weeks
Quadruplet Cohort: Objective Response Rate	ORR was defined as the percentage of participants with a confirmed CR or PR as per RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 139.9 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Triplet Cohort: Objective Response Rate	ORR was defined as the percentage of participants with a confirmed CR or PR as per RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 113 weeks
All Cohorts: Trough Concentration (Ctrough) of Tusamitamab Ravtansine	Blood samples were collected for the measurement of tusamitamab ravtansine concentrations.	Pre-dose on Day 1 of Cycle 2 (cycle duration=3 weeks)
All Cohorts: Ctrough of Pembrolizumab	Blood samples were collected for the measurement of pembrolizumab concentrations.	Pre-dose on Day 1 of Cycle 2 (cycle duration=3 weeks)
Quadruplet Cohort: Plasma Concentration of Pemetrexed	Blood samples were collected for the measurement of pemetrexed concentrations.	30 minutes post-dose on Day 1 of Cycle 1 (cycle duration=3 weeks)
Triplet and Quadruplet Cohorts: Total Plasma Concentration Observed at the End of Infusion (Ceoi) of Cisplatin	Blood samples were collected for the measurement of cisplatin concentrations.	At end of infusion on Day 1 of Cycle 1 (cycle duration=3 weeks)
Triplet and Quadruplet Cohorts: Total Plasma Concentration Observed at the End of Infusion of Carboplatin	Blood samples were collected for the measurement of carboplatin concentrations.	At end of infusion on Day 1 of Cycle 1 (cycle duration=3 weeks)
All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity or was a congenital anomaly/birth defect. A TEAE was defined as an AE that developed, worsened or became serious during the treatment-emergent period.	From first dose of study treatment (Day 1) up to 30 days post last dose of study treatment, approximately 162.4 weeks (doublet), 117 weeks (triplet), and 143.9 weeks (quadruplet)
Doublet and Quadruplet Cohorts: Progression-free Survival (PFS)	PFS was defined as the time from the first study treatment administration to the date of the first documented progressive disease (PD) or death due to any cause, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered progression.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 158.4 weeks (doublet) and 139.9 weeks (quadruplet)
All Cohorts: Disease Control Rate (DCR)	DCR was defined as percentage of participants with a confirmed CR, confirmed PR or stable disease (SD) as BOR per RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage from the baseline study to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered progression.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 158.4 weeks (doublet), 113 weeks (triplet), and 139.9 weeks (quadruplet)
All Cohorts: Duration of Response (DOR)	DOR was defined as the time from first documented evidence of CR or PR until PD determined per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered progression.	Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 158.4 weeks (doublet), 113 weeks (triplet), and 139.9 weeks (quadruplet)
All Cohorts: Number of Participants With Treatment-emergent Anti-Therapeutic Antibodies (ATAs) Against Tusamitamab Ravtansine	Blood samples were collected to assess the presence of treatment-emergent ATA against tusamitamab ravtansine. ATA incidence was defined as the number of participants found to have treatment-emergent ATA response during the study.	From first dose of study treatment (Day 1) up to 30 days post last dose of study treatment, approximately 162.4 weeks (doublet), 117 weeks (triplet), and 143.9 weeks (quadruplet)

Collaborators and Investigators

• Sponsor: Sanofi
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

Helpful Links

• ACT16146 Plain Language Results Summary

Study record dates

Study Major Dates

• Study Start (Actual): October 26, 2020
• Primary Completion (Actual): March 12, 2024
• Study Completion (Actual): December 24, 2024

Study Registration Dates

• First Submitted: August 20, 2020
• First Submitted That Met QC Criteria: August 20, 2020
• First Posted (Actual): August 24, 2020

Study Record Updates

• Last Update Posted (Estimated): October 29, 2025
• Last Update Submitted That Met QC Criteria: October 12, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Amino Acids, Peptides, and Proteins; Organic Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Inorganic Chemicals; Chlorine Compounds; Nitrogen Compounds; Coordination Complexes; Guanine; Hypoxanthines; Purinones; Purines; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Dicarboxylic; Platinum Compounds; Pemetrexed; Carboplatin; Cisplatin; pembrolizumab; tusamitamab ravtansine
• Other Study ID Numbers: ACT16146; U1111-1233-9798 (Registry Identifier: ICTRP); 2023-509115-84 (Registry Identifier: CTIS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No